Breaking AI & Tech News Analyzed

Tiger Woods, the renowned golf superstar, has made a significant decision to step down as the US captain for the 2027 Ryder Cup. This move allows him to focus on his health and well-being, following a recent court ruling that granted him permission to travel abroad for comprehensive inpatient treatment.A Florida judge approved Woods's request, citing his need for an “intensive, highly individualized and medically integrated program” away from media scrutiny. Woods's lawyer argued that his client's complex clinical presentation required a level of care that couldn't be safely provided in the United States.The decision comes on the heels of Woods's recent misdemeanor driving under the influence (DUI) charges following a rollover crash in Jupiter, Florida. Woods had pleaded not guilty to the charges, which included property damage and refusal to submit to a urinalysis. The incident revealed that Woods had been swearing profusely, showed signs of lethargy, and had extremely dilated pupils.Woods has been open about his need for treatment, stating that he aims to achieve lasting recovery. In a public statement, he expressed his commitment to prioritizing his health and seeking the necessary support. The PGA of America, PGA Tour, and Augusta National Golf Club have all offered their support for Woods during this challenging time.The PGA of America has announced that they will provide further updates on the Ryder Cup Captaincy when appropriate. For now, Woods's focus remains on his health and well-being, and the golf community rallies around him in support of his journey toward recovery.

President Donald Trump has announced a new policy threatening to impose 100% tariffs on US pharmaceutical companies that do not agree to lower their drug prices. This move is part of his effort to address the high cost of prescription medications in the US.The tariffs will specifically target branded drugs and their active ingredients, while generic drugs, which account for over 90% of medicines sold in the US, will be exempt for at least one year. Additionally, certain specialty drugs, such as orphan, veterinary, and other specialty drugs, will be exempt if they are from countries with which the US has a trade deal or meet urgent public health needs.Drugmakers that enter into pricing agreements with the White House and onshore drug production will be exempt from the tariffs. Companies planning to increase their domestic manufacturing will face a 20% tariff that will escalate to 100% over four years.The policy has been met with criticism from industry groups, such as the Midsized Biotech Alliance of America (MBAA), which argues that it creates an "unfair two-tiered system" that benefits large companies with diversified portfolios.Trump has been under pressure to lower drug prices, with US patients often paying nearly triple what patients pay in other developed nations. The announcement comes as the White House faces pressure from consumers to address rising costs amid other tariff-related price increases and high gas prices triggered by geopolitical tensions.

The usual visual language of hospital dramas relies on sterile whites and bright fluorescents. ‘What I’m Here For’ discards that palette entirely, immersing the audience in a world of black costumes and shadow‑filled set pieces.This daring aesthetic is the result of a collaboration between Vanishing Point of Glasgow and Teater Katapult from Aarhus, Denmark. Designer Mai Katsume outfits nurses, doctors and patients in deep black, arranging them in stark rows that dominate an ominously dark stage.At the centre stands Lærke Schjærff Engelbrecht as Flora, a nurse forced onto an extra weekend shift because of chronic short‑staffing. Even the flickering strip lights beneath her feet are cloaked in darkness, a visual choice amplified by Simon Wilkinson’s austere lighting design that drains the scene of any residual warmth, turning a hectic night ward into a gothic horror tableau.Written by Josephine Eusebius and performed in a blend of Danish and English, the script follows a familiar premise—too many patients, too few staff—but pushes it to a psychological extreme. Flora cheerfully repeats the hospital‑as‑hotel mantra while confronting impossible choices, such as whether to prioritize a pleasant woman with a brain tumour in room 22 or a demanding lady with a heart condition in room 33.The tension is heightened by Mark Melville’s pulse‑driven soundtrack, a low‑frequency thrum that underscores Flora’s isolation. As in many of director Matthew Lenton’s productions, the protagonist is both integral to and alienated from the medical team, a duality made palpable by her physical separation from the other actors and their disembodied commentary.Throughout the performance, Flora remains downstage, engaging in dream‑like exchanges with colleagues whose looming presence becomes as oppressive as the life‑and‑death decisions she must make. The staging forces the audience to feel the weight of each moral dilemma, turning routine triage into an almost tactile nightmare.‘What I’m Here For’ runs at the Tron in Glasgow until 4 April and will tour to other venues until 18 April.

The United States Supreme Court issued an 8‑1 decision on Tuesday that invalidated Colorado’s law prohibiting “conversion therapy” for LGBTQ minors. The majority held that the ban infringed on the First Amendment’s free‑speech guarantees, arguing that even therapeutic dialogue falls under protected expression. Justice Elena Kagan wrote that when a state suppresses one side of a debate while supporting the other, the constitutional issue is “straightforward.” In contrast, Justice Neil Gorsuch emphasized that the First Amendment “stands as a shield against any effort to enforce orthodoxy in thought or speech.” Only Justice Ketanji Brown Jackson dissented, warning that the ruling “threatens to impair states’ ability to regulate the provision of medical care” and underscored the documented harms of conversion therapy to LGBTQ youth. Colorado’s 2019 statute barred any “practice or treatment” aimed at changing a child’s gender identity or sexual orientation, though it allowed discussion of religion, gender, and sexuality. No individual has yet been sanctioned under the law. The case was brought by Christian counselor Kaley Chiles, who argued that the ban prevented her from offering voluntary, faith‑based talk therapy, a position backed by the administration of former President Donald Trump. Approximately two dozen states have enacted similar bans, reflecting a growing consensus that conversion therapy is both ineffective and harmful. Scientific studies link the practice to higher rates of depression and suicidal ideation among LGBTQ individuals. Major medical associations have condemned it as a dangerous, discredited intervention. Advocates for LGBTQ rights criticized the Court’s ruling as a setback. Polly Crozier, director of family policy at GLAD Law, said, “This is a dangerous practice that has been condemned by every major medical association in the country. Today’s decision does not change the science, and it does not change the fact that conversion therapists who harm patients will still face legal consequences.” The decision is expected to make enforcement of existing bans more difficult, potentially prompting a wave of legal challenges in other jurisdictions that have sought to protect LGBTQ youth from conversion therapy.

Tiger Woods has withdrawn from the opportunity to lead the United States team as captain at the 2027 Ryder Cup. The PGA of America announced this decision after Woods announced he would be stepping away from golf to focus on his health and wellbeing. The 15-time major winner was the favourite to take on the role for the US at the Irish resort of Adare Manor. However, following a recent car accident and a DUI charge, Woods has decided to prioritize his health. Woods was involved in a car accident last week where he clipped a trailer and rolled his Land Rover. Police reported that he showed signs of impairment, and investigators found two white pills identified as hydrocodone during a search of his vehicle. A statement from the PGA of America read: “We commend Tiger for prioritising his long-term health and deeply respect the courage it takes to make such a personal decision.” The organization will share further updates regarding the Ryder Cup captaincy when appropriate. Woods has undergone numerous surgeries throughout his career, particularly to his leg and ankle, after suffering multiple injuries in a serious crash in 2021. He was granted permission by a Florida judge to leave the US to enter a comprehensive inpatient treatment facility as he faces misdemeanor driving under the influence charges. The Martin County court judge, Darren Steele, granted the motion to travel submitted by Woods’ attorney, citing the golf superstar’s need for an “intensive, highly individualized and medically integrated program” away from media and public scrutiny.

The U.S. Food and Drug Administration announced on Wednesday that it has granted expedited approval to Eli Lilly’s oral weight‑loss medication, orforglipron—marketed under the brand name Foundayo. This makes Foundayo the second GLP‑1 pill to reach U.S. consumers, following Novo Nordisk’s Wegovy tablet approved in December. Orforglipron works by mimicking a natural hormone that regulates appetite and satiety, offering a non‑injectable alternative to existing GLP‑1 injectables. David A. Ricks, Eli Lilly’s chair and CEO, highlighted that fewer than one in ten eligible patients are currently using GLP‑1 therapies, citing barriers such as cost, stigma, and perceived complexity. Unlike Wegovy, which must be taken on an empty stomach each morning, Foundayo can be taken anytime of day regardless of meals, simplifying dosing schedules. Patients will start on a low dose that is gradually increased to mitigate side‑effects. Pricing is projected at $149 per month for the initial dose, with higher‑strength formulations potentially reaching $349 monthly. While private‑insurance coverage remains uncertain, a Trump‑administration proposal could allow Medicare to cover certain patients as early as this summer, with copayments as low as $50 per month. Distribution will commence on Monday through LillyDirect’s direct‑to‑consumer channel, with broader availability in pharmacies and telehealth platforms expected shortly thereafter. The convenience of a once‑daily pill is anticipated to improve adherence, especially for individuals who avoid injectables due to needle aversion or rigid dosing requirements. The approval follows a fast‑track submission submitted only months ago, positioning Foundayo to enter the market roughly three months after Wegovy. This rapid rollout is set to intensify competition in the burgeoning GLP‑1 space, where new agents are continually emerging with claims of better efficacy and lower costs.

Palantir’s claim that opposition to its NHS contract is driven by ideology was rebuked by Chi Onwurah, the Labour MP who chairs Parliament’s science, innovation and technology select committee. Onwurah said it is appropriate for ministers to explore a break‑clause option in the deal, underscoring the seriousness of the concerns raised. Louis Mosley, Palantir’s UK executive vice‑chair, had urged the government not to succumb to “ideologically motivated campaigners” as officials weighed a way out of a £330 million contract to deliver the Federated Data Platform (FDP) for NHS England. Ministers have now asked for advice on triggering the contract’s break clause amid growing scrutiny of Palantir’s expanding role in the public sector. The FDP is an AI‑enabled platform designed to integrate disparate health information across the NHS. Palantir already holds contracts with the Ministry of Defence, several police forces and the UK’s financial watchdog, the FCA. Onwurah’s cross‑party committee is set to publish its report in the coming weeks, covering the digital reorganisation of government services and the role of AI after a series of hearings that included experts, NHS leaders and representatives from companies such as Palantir. She identified three core issues: the manner in which the contract was awarded, the handling of patient data and the resulting trust deficit within the NHS, and the involvement of Peter Mandelson through his firm Global Counsel. “These are not fringe ideological concerns,” Onwurah told the Guardian. “They relate to contract transparency, vendor lock‑in, value for money and data security – matters that should concern everyone pushing the NHS towards digital transformation.” She added that the NHS’s post‑COVID fatigue and austerity‑driven burnout make any additional trust‑related resentment a significant barrier to progress. Onwurah noted that Palantir secured the contract after providing services to the NHS at a nominal cost – a tactic often used by large tech firms to position themselves as the most attractive government supplier. “It is right for the government to explore all options, including breaking the contract, given ongoing concerns about FDP uptake while Palantir remains at the helm,” she said. Liberal Democrat MP Martin Wrigley, also on the committee, urged the government to commission a new consortium of UK‑based tech experts to build a home‑grown NHS platform. During a previous committee appearance, Mosley accused British doctors of placing “ideology over patient interest” after they challenged the data‑processing contract. Speaking to the Times, Mosley warned that removing Palantir could jeopardise patient care and stall solutions to the NHS’s biggest challenges, arguing that the campaign against the firm would do more harm than good.

The Tyre hospital in Lebanon has faced significant challenges, being hit five times since the start of Israel's attacks on the country. This escalation of violence has raised concerns about the humanitarian situation in the region.The repeated strikes on the hospital have likely disrupted medical services and put the lives of patients and staff at risk. The situation remains volatile, with ongoing tensions between Israel and Lebanon contributing to the uncertainty.

Palantir’s senior UK representative has warned ministers against yielding to ideologically motivated campaigners as they explore the possibility of terminating a £330 million NHS contract for the company’s Federated Data Platform (FDP).The FDP, an AI‑enabled system intended to unify patient information across the health service, is part of a broader portfolio that includes contracts with the Ministry of Defence, several police forces and the UK’s financial regulator.Louis Mosley, executive vice‑chair of Palantir UK, told The Times that abandoning the deal would jeopardise patient care and hinder progress on the NHS’s most pressing challenges. He highlighted that the platform is projected to generate £150 million in benefits by the end of the decade, delivering a £5 return for every pound spent.According to the Financial Times, senior officials have begun informal discussions about activating a break clause that would allow the FDP’s operation to be transferred to an alternative provider once the system becomes fully operational next year.Palantir, a US‑based data‑analytics firm with ties to the Israeli and US militaries and former U.S. Immigration and Customs Enforcement contracts, has faced sustained opposition from the British Medical Association, which has long criticised the use of its technology in patient‑care settings.Health officials acknowledge the reputational risk, noting that the controversy now extends beyond traditional Labour‑left and Green Party critics. A Department of Health and Social Care spokesperson emphasised that the FDP is designed to improve care coordination, accelerate cancer diagnoses and increase treatment capacity, while maintaining strict data‑security safeguards.Health Secretary Wes Streeting, speaking on the Guardian Politics Weekly podcast, recognised public unease about Palantir’s political affiliations, referencing founder Peter Thiel’s right‑wing connections. He reassured listeners that Palantir does not have direct access to patient data, stating, "The platform is operated by us; Palantir never sees the data."Adoption of Palantir’s technology within the NHS has risen from 118 to 151 organisations since June, though it remains short of the government’s target of 240 organisations by year‑end. Labour backbencher Clive Lewis noted that the issue is becoming a visible concern for voters, reflecting broader anxieties about AI and foreign‑owned infrastructure in critical public services.